JB Pharma Q1 Profit, Margin Climb

  Published 11 months ago

JB Pharma's Q1 FY26 PBT rose 13.25% YoY to Rs 271.61 crore, with the operating EBITDA margin crossing the 30% milestone.

  • Operating EBITDA grew 13% YoY to Rs 330 crore, with margin rising to 30.2% from 29% last year.
  • Domestic business saw 14% value growth, led by acute, chronic, and ophthalmology segment performance.
  • CDMO segment remains strong, with JB Pharma focused on topline growth, cost control, and sustained profitability.

You might like these

India's Forex Reserves Dip to $685.729 Billion

India-Cyprus Business Summit 2024: Strengthening Economic Ties

Foreign Investors Boost India Bonds

Hyundai Motor India Stock Surges, Hits All Time High

AdaniConneX Acquires GRPL for Infrastructure Expansion

Hindustan Zinc Q2 FY26 Profit Jumps 13.83%

India Seeks Gold Loan Rule Relaxations

News that matters the most ⚡